Clinical Trials List
2022-10-17 - 2025-09-26
Phase I
Recruiting1
Terminated2
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.09
Secondary carcinoid tumors of other sites
ICD-10C7B.1
Secondary Merkel cell carcinoma
ICD-10C7B.8
Other secondary neuroendocrine tumors
ICD-10C80.0
Disseminated malignant neoplasm, unspecified
ICD-10D3A.8
Other benign neuroendocrine tumors
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.0
Disseminated malignant neoplasm
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/01
Investigators and Locations
Co-Principal Investigator
- Jeng-Shiun Du 無
- Tsung-Jang Yeh 無
- 高育青 無
- I-CHEN WU 無
- Yi-Hsun Chen 無
- Hui-Ching Wang 無
- 莊哲明 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chih-Chieh Yen 無
- 劉奕廷 無
- Shang-Yin Wu 無
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 徐偉勛 無
- Wei-Wu Chen 無
- Jih-Hsiang Lee 無
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
4 participants
-
Global
40 participants
